‘Difficult explanation’over the lobbying of the Pfizer Korea’s ‘Xalkori Cap’

Published: 2014-12-12 13:02:10

Updated: 2014-12-12 13:43:15

When it comes to lobbying of the Pfizer Korea’s ‘Xalkori Cap’on the Drug Price Evaluation Committee (DPEC), the Health Insurance Review & Assessment Service (HIRA) has continuously released explanations.

After making the first explanation on the 4^th, the HIRA gave a lame excuse stating “It is true that Pfizer Korea tried to reach a member of the DPEC, a contact never has been made.”

Excommuni...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.